Cabaletta Bio sets 2027 BLA target for myositis therapy amid manufacturing pivot
Cabaletta Bio (NASDAQ:CABA) today reported financial results for the fourth quarter and full year ended December 31, 2025, providing a definitive timeline for the regulatory submission of its lead product candidate.











